The frequency of illegitimate V(D)J recombinase-mediated mutations in children treated with etoposide-containing antileukemic therapy

Mutation Research - Genetic Toxicology and Environmental Mutagenesis

Volumn 419, Issue 1-3, 1998, Pages 107-121

  Fuscoe, James C ^a   Knapp, Geremy W ^a   Hanley, Nancy M ^a   Setzer, R Woodrow ^b   Sandlund, John T ^c   Pui, Ching Hon ^c   Relling, Mary V ^c  

^a U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

^b US Environ P   (United States)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

ALL; bcl 2; Chemotherapy; Deletion; Etoposide; hprt; IgH; Mutagenesis; Translocation; V(D)J recombination

Indexed keywords

CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; MERCAPTOPURINE; METHOTREXATE;

ADOLESCENT; ADULT; ARTICLE; BLOOD CELL; CELL TYPE; CHEMOTHERAPY; CHILD; CHROMOSOME TRANSLOCATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DNA DETERMINATION; DNA SEQUENCE; FEMALE; HUMAN; HUMAN CELL; INFANT; LEUKEMIA; LYMPHOCYTE; MALE; MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REMISSION; RISK FACTOR; SECOND CANCER;

BASE SEQUENCE; CHILD; CHILD, PRESCHOOL; CHROMOSOME ABERRATIONS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 14; CHROMOSOMES, HUMAN, PAIR 18; DNA NUCLEOTIDYLTRANSFERASES; ETOPOSIDE; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE; LYMPHOCYTES; POLYMERASE CHAIN REACTION; TRANSLOCATION, GENETIC; VDJ RECOMBINASES;

EID: 0032501167     PISSN: 13835718     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1383-5718(98)00129-6     Document Type: Article

References (44)

1. Clark P.I., Slevin M.L. The clinical pharmacology of etoposide and teniposide. Clin. Pharmacokinet. 12:1987;223-252.
2. Ferguson L.R., Baguley B.C. Topoisomerase II enzymes and mutagenicity. Environ. Mol. Mutagen. 24:1994;245-261.
3. Pui C.-H., Ribeiro R., Hancock M.L., Rivera G.K., Evans W.E., Raimondi S., Head D.R., Behm F.G., Mahmoud M.H., Sandlund J.T., Crist W. Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphocytic leukemia. N. Engl. J. Med. 325:1991;1682-1687.
4. Smith M.A., Rubinstein L., Ungerleider R.S. Therapy-related acute myeloid leukemia following treatment with epipodophyllotoxins: estimating the risks. Med. Pediatr. Oncol. 23:1994;86-98.
5. Tkachuk D.C., Kohler S., Cleary M.L. Involvement of a homolog of Drosophila trithorax by 11q23 chromosomal translocations in acute leukemias. Cell. 13:1992;691-700.
6. Negrini M., Felix C.A., Martin C., Lange B.J., Nakamura T., Canaani E., Croce C.M. Potential topoisomerase II DNA-binding sites at the breakpoints of a t(9;11) chromosome translocation in acute myeloid leukemia. Cancer Res. 53:1993;4489-4492.
7. Felix C.A., Lange B.J., Hosler M.R., Fertala J., Bjornsti M.A. Chromosome band 11q23 translocation breakpoints are DNA topoisomerase II cleavage sites. Cancer Res. 55:1995;4287-4292.
8. Gu Y., Alder H., Nakamura T., Schichman S.A., Prasad R., Canaani O., Saito H., Croce C.M., Canaani E. Sequence analysis of the breakpoint cluster region in the ALL-1 gene involved in acute leukemia. Cancer Res. 54:1994;2326-2330.
9. Domer P.H., Fakharzadeh S.S., Chen C.S., Jockel J., Johansen L., Silverman G.A., Kersey J.H., Korsmeyer S.J. Acute mixed-lineage leukemia t(4;11)(q21;q23) generates an MLL-AF4 fusion product. Proc. Natl. Acad. Sci. U.S.A. 90:1993;7884-7888.
10. Gu Y., Cimino G., Alder H., Nakamura T., Prasad R., Canaani O., Moir D.T., Jones C., Nowell P.C., Croce C.M., Canaani E. The (4;11)(q21;q23) chromosome translocations in acute leukemias involve the VDJ recombinase. Proc. Natl. Acad. Sci. U.S.A. 89:1992;10464-10468.
11. Rabbitts T.H. Chromosomal translocations in human cancer. Nature. 372:1994;143-149.
12. Height S.E., Dainton M.G., Kearney L., Swansbury G.J., Matutes E., Dyer M.J.S., Treleaven J.G., Powles R.L., Catovsky D. Acute myelomonocytic leukemia with t(10;11)(p13;q23): heterogeneity of breakpoints at 11q23 with recombinase activation. Genes Chromosomes Cancer. 11:1994;136-139.
13. Yarkoni S., Lishner M., Tangi H., Nagler A., Lorberboum-Galski H. B-cell non-Hodgkin's lymphoma: evidence for the t(14:18) translocation in all hematopoietic cell lineages. J. Natl. Cancer Inst. 88:1996;973-979.
14. Williams L., Moscinski L.C. Sterile transcription of immunoglobulin/T-cell receptor genes and other evidence of early lymphoid differentiation in acute myelogenous leukemia. Leukemia. 7:1993;1423-1431.
15. Menetski J.P., Gellert M. V(D)J recombination activity in lymphoid cell lines is increased by agents that elevate cAMP. Proc. Natl. Acad. Sci. U.S.A. 87:1990;9324-9328.
16. McGregor W.G., Maher V.M., McCormick J.J. Kinds and locations of mutations induced in the hypoxanthine-guanine phosphoribosyltransferase gene of human T-lymphocytes by 1-nitrosopyrene, including those caused by V(D)J recombinase. Cancer Res. 54:1994;4207-4213.
17. Lipkowitz S., Garry V.F., Kirsch I.R. Interlocus V-J recombination measures genomic instability in agriculture workers at risk for lymphoid malignancies. Proc. Natl. Acad. Sci. U.S.A. 89:1992;5301-5305.
18. Fuscoe J.C., Zimmerman L.J., Harrington-Brock K., Burnette L., Moore M.M., Nicklas J.A., Jp O.N., Albertini R.J. V(D)J recombinase-mediated deletion of the hprt gene in T-lymphocytes from adult humans. Mutat. Res. 283:1992;13-20.
19. Fuscoe J.C., Vira L.K., Collard D.D., Moore M.M. Quantification of hprt gene deletions mediated by illegitimate V(D)J recombination in peripheral blood cells of humans. Environ. Mol. Mutagen. 29:1997;28-35.
20. Fuscoe J.C., Setzer R.W., Collard D.D., Moore M.M. Quantification of t(14;18) in the lymphocytes of healthy adult humans as a possible biomarker for environmental exposures to carcinogens. Carcinogenesis. 17:1996;1013-1020.
21. Chen C.L., Fuscoe J.C., Liu Q., Pui C.H., Mahmoud H.H., Relling M.V. Relationship between cytotoxicity and site-specific DNA recombination after in vitro exposure of leukemia cells to etoposide. J. Natl. Cancer Inst. 88:1996;1840-1847.
22. Chen C.L., Fuscoe J.C., Liu Q., Relling M.V. Etoposide causes illegitimate V(D)J recombination in human lymphoid leukemic cells. Blood. 88:1996;2210-2218.
23. C.-H., Pui, G.K. Rivera, M.L. Hancock, J.T. Sandlund, R.C. Ribeiro, J. Boyett, M.V. Relling, W.E. Evans, W.M. Crist, Risk-adapted treatment for acute lymphoblastic leukemia: findings from St. Jude Children's Research Hospital, in: T. Buchner, G. Schellong, W. Hiddemann, D. Urbanitz, J. Ritter (Eds.), Acute Leukemias VI. Prognostic Factors and Treatment Strategies, Springer-Verlag, Berlin, 1997, pp. 629-637.
24. Rivera G.K., Raimondi S.C., Hancock M.L., Behm F.G., Pui C.-H., Abromowitch M., Mirro J., Ochs J., Look A.T., Murphy S.B., Dahl G.V., Kalwinsky D.K., Evans W.E., Kun L., Simone J.V., Crist W.M. Improved outcome in childhood acute lymphoblastic leukemia with reinforced early treatment and rotational combination chemotherapy. Lancet. 337:1991;61-66.
25. Edwards A., Voss H., Rice P., Civitello A., Stegemann J., Schwager C., Zimmermann J., Erfle H., Caskey C.T., Ansorge W. Automated DNA sequencing of the human HPRT locus. Genomics. 6:1990;593-608.
26. Fuscoe J.C., Zimmerman L.J., Lippert M.J., Nicklas J.A., O'Neill J.P., Albertini R.J. V(D)J recombinase-like activity mediates hprt gene deletion in human fetal T-lymphocytes. Cancer Res. 51:1991;6001-6005.
27. K.S. Crump, R. Howe, Statistical confidence limits in low-dose extrapolation, in: D.B. Clayson, D. Krewski, I. Munro (Eds.), Toxicological Risk Assessment, Vol. I, CRC Press, Boca Raton, 1985, pp. 187-203.
28. Pui C.H., Kane J.R., Crist W.M. Biology and treatment of infant leukemias. Leukemia. 9:1995;762-769.
29. Bernard O.A., Berger R. Molecular basis of 11q23 rearrangements in hematopoietic malignant proliferations. Genes Chromosomes Cancer. 13:1995;75-85.
30. Winick N.J., McKenna R.W., Shuster J.J., Schneider N.R., Borowitz M.J., Bowman W.P., Jacaruso D., Kamen B.A., Buchanan G.R. Secondary acute myeloid leukemia in children with acute lymphoblastic leukemia treated with etoposide. J. Clin. Oncol. 11:1993;209-217.
31. Perera F.P., Motzer R.J., Tang D., Reed E., Parker R., Warburton D., O'Neill P., Albertini R., Bigbee W.L., Jensen R.H., Santella R., Tsai W.-Y., Simon-Cereijida G., Randall C., Bosl G. Multiple biological markers in germ cell tumor patients treated with platinum-based chemotherapy. Cancer Res. 52:1992;3558-3565.
32. Hirota H., Kubota M., Adachi S., Okuda A., Lin Y.W., Bessho R., Wakazono Y., Matsubara K., Kuwakado K., Akiyama Y., Tsutsui T. Somatic mutations at T-cell antigen receptor and glycophorin A loci in pediatric leukemia patients following chemotherapy: comparison with HPRT locus mutation. Mutat. Res. 315:1994;95-103.
33. Tates A.D., van Dam F.J., Natarajan A.T., Zwinderman A.H., Osanto S. Frequencies of HPRT mutants and micronuclei in lymphocytes of cancer patients under chemotherapy: a prospective study. Mutat. Res. 307:1994;293-306.
34. Abdallah J.M., Lombardi D.P., Kirsch I.R. Genetic instability in patients with Hodgkin's disease undergoing chemotherapy. J. Clin. Invest. 96:1995;2744-2747.
35. Karnaoukhova L., Moffat J., Martins H., Glickman B. Mutation frequency and spectrum in lymphocytes of small cell lung cancer patients receiving etoposide chemotherapy. Cancer Res. 57:1997;4393-4407.
36. Schichman S.A., Caligiuri M.A., Strout M.P., Carter S.L., Gu Y., Canaani E., Bloomfield C.D., Croce C.M. ALL-1 tandem duplication in acute myeloid leukemia with a normal karyotype involves homologous recombination between Alu elements. Cancer Res. 54:1994;4277-4280.
37. Megonigal M.D., Rappaport E.F., Jones D.H., Kim C.S., Nowell P.C., Lange B.J., Felix C.A. Panhandle PCR strategy to amplify MLL genomic breakpoints in treatment-related leukemias. Proc. Natl. Acad. Sci. U.S.A. 94:1997;11583-11588.
38. Domer P.H., Head D.R., Renganathan N., Raimondi S.C., Yang E., Atlas M. Molecular analysis of 13 cases of MLL/11q23 secondary acute leukemia and identification of topoisomerase II consensus-binding sequences near the chromosomal breakpoint of a secondary leukemia with the t(4;11). Leukemia. 9:1995;1305-1312.
39. Broeker P.L., Super H.G., Thirman M.J., Pomykala H., Yonebayashi Y., Tanabe S., Zeleznik-Le N., Rowley J.D. Distribution of 11q23 breakpoints within the MLL breakpoint cluster region in de novo acute leukemia and in treatment-related acute myeloid leukemia: correlation with scaffold attachment regions and topoisomerase II consensus binding sites. Blood. 87:1996;1912-1922.
40. Cimino G., Rapanotti M.C., Biondi A., Elia L., Coco F.L., Price C.M., Rossi V., Rivory L., Canaani E., Croce C.M., Mandelli F., Greaves M. Infant acute leukemias show the same biased distribution of ALL1 gene breaks as topoisomerase II related secondary acute leukemias. Cancer Res. 57:1997;2879-2883.
41. Liu Y., Hernandez A.M., Shibata D., Cortopassi G.A. BCL2 translocation frequency rises with age in humans. Proc. Natl. Acad. Sci. U.S.A. 91:1994;8910-8914.
42. Coustan-Smith E., Behm F.G., Sanchez J., Boyett J.M., Hancock M.L., Raimondi S.C., Rubnitz J.E., Rivera G.K., Sandlund J.T., Pui C.-H., Campana D. Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia. Lancet. 351:1998;550-554.
43. Cleary M.L., Smith S.D., Sklar J. Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2/immunoglobulin transcript resulting from the t(14;18) translocation. Cell. 47:1986;19-28.
44. Ravetch J.V., Siebenlist U., Korsmeyer S., Waldmann T., Leder P. Structure of human immunoglobulin mu locus: Characterization of embryonic and rearranged J and D genes. Cell. 27:1981;583-591.